GSK Loses Expert Defense In Upcoming Zantac lawsuit March 24 (Reuters) - A California judge on Thursday rejected GSK Plc's request to withhold expert testimony linking the discontinued antidepressant Zantac to cancer in an upcoming trial, signaling a setback for the drugmaker. Britain is facing legal action over the drug in the United States. State. across the United States. GSK shares fell 3.6% on Friday. Analysts said that the judgment of Alameda County Superior Court Judge Evalio Grillo is not surprising, and that the case may affect the prices of drug dealers until the trial begins on July 24. The Trial Will Be The First Test Of Zantac's Cancer Claims To Go Before A Jury. "Our client will have his day in court, and we look forward to presenting to the jury evidence that GSK has known for decades that Zantac has significant carcinogenic potential," said Jennifer Moore, an attorney for Goetz and others. Another Zantac chaser said. . , said in a statement. ...